Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

CTSH · Q3 2025 Earnings

Cognizant

Reported October 29, 2025

30-second summary

Cognizant grew revenue 7.4% YoY to $5.42B in Q3, clearing its own guide by $65M and beating the prior constant-currency growth range (3.5–5.0%) by ~240bps. Management raised the FY2025 constant-currency growth floor by 200bps to 6.0–6.3%, lifted EPS by $0.14 at the low end to $5.22–$5.26, and pushed operating margin to the top of the prior band at ~15.7%. The tension: Q4 is guided to just 2.5–3.5% constant-currency growth — a material step-down that management is framing as conservatism but which the print does not fully explain.

Headline numbers

EPS

Q3 FY2025

$1.39

Revenue

Q3 FY2025

$5.42B

+7.4% YoY

Gross margin

Q3 FY2025

33.9%

Free cash flow

Q3 FY2025

$1.16B

Operating margin

Q3 FY2025

16.0%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$5.42B	+7.4%	$5.25B	+3.2%
EPS	$1.39	—	$1.31	+6.1%
Gross margin	33.9%	—	33.7%	+20bps
Operating margin	16.0%	—	15.6%	+40bps
Free cash flow	$1.16B	—	$0.33B	+250.5%

Guidance

Company raised FY2025 full-year revenue growth guidance to 6.0-6.3% (constant currency) and EPS to $5.22-$5.26, driven by Q3 beat of 7.4% YoY revenue growth; Q4 expected to decelerate sharply to 2.5-3.5% constant currency growth.

Guidance is issued for both next quarter and the full year. Both may appear below.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q3 FY2025	$5.27 - $5.35 billion	$5.415 billion	+0.065 billion above high end of guide	Beat
Revenue growth YoY (constant currency)	Q3 FY2025	3.5% to 5.0%	7.4%	+2.4 to +3.9 pts above high end of guide	Beat

New guidance

Metric	Period	Guide	YoY
Revenue growth YoY (constant currency)	Q4 FY2025	2.5% to 3.5%	2.5% to 3.5%
Revenue	Q4 FY2025	$5.27 - $5.33 billion	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY 2025	$20.7 - $21.1 billion	$21.05 - $21.10 billion	+$0.35B to +$0.40B midpoint increase	Raised
Revenue growth YoY (constant currency)	FY 2025	4.0% to 6.0%	6.0% to 6.3%	+0 to +0.3 pts at high end; raised low end by 200 bps	Raised
Adjusted Operating Margin	FY 2025	15.5% to 15.7%	approximately 15.7%	raised to high end (15.7%) from range midpoint	Raised
Adjusted Diluted EPS	FY 2025	$5.08 to $5.22	$5.22 to $5.26	+$0.14 to +$0.18 at low end; +$0.04 at high end	Raised

Segment performance

Q3 FY2025

Segment	Q3 FY2025	YoY
Health Sciences	$1.604B	+5.9%
Financial Services	$1.578B	+6.2%
Products and Resources	$1.383B	+12.6%
Communications, Media and Technology	$0.85B	+4.2%

Platform metrics

Q3 FY2025

Segment	Q3 FY2025
Trailing 12-Month Bookings	$27.5 billion
Book-to-Bill Ratio	1.3x
Large Deals (TCV $100M+)	6 deals signed in Q3; 16 YTD
Large Deal TCV YTD Growth	40% YoY
Total Headcount	349,800
Voluntary Attrition - Tech Services (TTM)	14.5%

Profitability

Q3 FY2025

Segment	Q3 FY2025
Adjusted Operating Margin	16.0%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
North America	$4.028B	+7.8%
Europe	$1.042B	+7.8%
Rest of World	$0.345B	+0.9%
Year-to-Date Capital Returns	$1.5 billion (share repurchases and dividends)	—

Management tone

Q4-2024 customer-spend caution → Q1-2025 AI pilot scaling → Q2-2025 "new spend cycle" reframe → Q3-2025 builder/platform identity entrenched

The Q2 reframe — AI as a separate spend cycle rather than a productivity tailwind — has now hardened into an identity claim. Where last quarter management was asserting that agentic AI unlocks new spend pools, this quarter they are asserting that Cognizant itself is being remade as a "builder" rather than an integrator. The verbatim anchor: "Becoming an AI builder means building the platforms and engineering capabilities that enable agentic AI to scale across the enterprise." This is no longer a positioning statement about deals — it is a positioning statement about the company. The signal is that management believes the IP layer is now load-bearing for the equity story, not optional.

The unit-economics framing has shifted from aspirational to evidentiary. In Q2, management argued innovation-led deals would be monetized linearly without sharing productivity gains back to clients. In Q3, they are pointing to revenue per employee +8% YoY and operating margin income per employee +10% YoY as proof that the model is already decoupling from headcount. The anchor: "It's indicative of how we are becoming an AI builder company with platforms, intellectual property, software, and services all bundled together." If those per-employee figures hold or expand in 2026, the multiple-rerating case has a foothold. If they revert, the "builder" narrative loses its quantitative backstop.

The large-deal narrative has bifurcated explicitly for the first time. Q1 and Q2 framed large deals as consolidation/cost-takeout wins. This quarter management said "in 23 and 24, the swim lane was productivity. And in 25, we are starting to see innovation-led, agentic capital-led" deals. The 40% YoY growth in large-deal TCV YTD is being attributed to this new lane, not to share gains in the old one. The implication is that the deal mix is structurally changing — if true, it warrants different gross margin and ramp assumptions than historical large deals carried.

Hedging is concentrated narrowly on Q4 visibility — "if things could go a little worse then it's the bottom end and if we can get some additional momentum…then it's upper end" — and on the discretionary backdrop in tariffs, healthcare funding, and Europe. This is the same hedging frame as Q2, unchanged in scope, which makes the Q4 cc guide of 2.5–3.5% read more as bookings-to-revenue conversion friction than as a demand crack.

Recurring themes management leaned on this quarter:

AI-builder identity: IP and platforms ownership as competitive moatNon-linear growth via fixed-price/outcome-based delivery and AI-enabled productivityThree-vector monetization: productivity (FlowSource), industrialized AI (Agent Foundry, context engineering), and agentification of enterprise (ADLC replacing SDLC)BPO/BPaaS acceleration (10% growth) as primary vector 3 revenue channelLarge deal momentum (16 YTD, 40% TCV growth) shifting from consolidation to innovation spendOrganizational AI fluency: 250,000+ employees trained; 30% internal code AI-generated; freshers hiring strategy doubled

Risks management surfaced:

Trade policy uncertainty and tariff impacts on client discretionary spendingGeopolitical backdrop affecting Europe and rest-of-world demand stabilityGovernment funding uncertainty in healthcare verticalLarge deal ramp diluting gross margins and utilization in near termExecution risk on IP monetization and platform adoption at scale

Answers to last quarter's watch list

Q4 exit-rate landing within the disclosed -0% to ~4% range. Q4 cc guide of 2.5–3.5% lands in the upper half of the prior range — at or above the ~1% midpoint management had signaled. The FY guide raise implies management has higher confidence in the lower-deceleration scenario than the August commentary suggested.

Resolved positively

Vector 3 (agentification) project count trajectory. Management did not disclose an updated project count for Q3. The narrative shifted from project-count metrics to a three-vector revenue framing (productivity, industrialized AI, agentification) and BPO/BPaaS at +10% growth was called out as the primary Vector 3 revenue channel. The metric framework has changed — not the underlying activity.

Not resolved

Large-deal cadence vs the 29-in-2024 / 17-in-2023 baseline. 6 deals in Q3, 16 YTD with TCV +40% YoY. At this pace Cognizant will narrowly miss 2024's 29-deal count on volume but exceed it materially on TCV — consistent with the management thesis that deal size is expanding via innovation spend.

Resolved positively

Adjusted operating margin holding ≥15.6% in Q3. Q3 adjusted operating margin came in at 16.0%, well above the 15.6% threshold and above the 15.5–15.7% FY band. Management absorbed the headcount step-up without compression and now guides FY to the top of the range.

Resolved positively

Healthcare segment growth sustaining above ~6%. Health Sciences at +5.9% YoY, fractionally below the 6% threshold and a 30bps deceleration from Q2's +6.2%. Not a crack, but the trajectory bears watching as government funding uncertainty was flagged in risks.

Continue monitoring

Constant-currency growth landing in the upper half of the narrowed FY range. The FY range itself was raised from 4.0–6.0% to 6.0–6.3%, putting the new floor 200bps above the prior floor. The original "upper half" question is moot because the range moved entirely upward.

Resolved positively

What to watch into next quarter

Whether Q4 cc growth prints above the guided 2.5–3.5% range — Q3 beat its cc guide by ~240bps. A repeat would imply 5%+ Q4 cc growth and a clean FY landing above 6.3%; a print inside the range validates the deceleration concern.

Revenue per employee and adjusted operating income per employee in Q4 — the 8% and 10% YoY figures are the quantitative backbone of the "builder" narrative. Watch whether these expand or compress as headcount continues to rise (now 349,800).

Products and Resources segment growth — decelerated 340bps QoQ to +12.6%. Another step-down would suggest the large-deal ramp tailwind from Belcan and tariff-affected verticals is rolling off, not normalizing.

Health Sciences holding ≥5.5% — already below the 6% threshold from last quarter. Government funding pressure in healthcare was newly emphasized in this quarter's risks; a slip into the 4s would be the first material vertical crack.

2026 initial revenue guide framing — given management's "very proud" framing on hitting the high end of the original February 2025 guide and the structural builder/platform narrative, the February 2026 initial guide will be the first explicit test of whether the AI-builder identity translates to a higher growth algorithm than the 4–6% historical band.

Whether the agentic project count or a successor metric reappears in disclosure — Q3 dropped the 2,500-project metric in favor of vector revenue framing. If management cannot point to a quantitative agentic adoption metric next quarter, the credibility of the "new spend cycle" claim weakens.

Sources

Cognizant Q3 2025 press release (Exhibit 99.1, Form 8-K filed 2025-10-29) — https://www.sec.gov/Archives/edgar/data/1058290/000105829025000338/exhibit9919302025.htm
Cognizant Q3 2025 earnings call prepared remarks (per extraction; no full transcript available)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.